Merck, Inc.
🇵🇭Philippines
Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888)
Phase 2
Completed
- Conditions
- Cough
- Interventions
- Drug: SCH 619734Drug: Placebo Dose 1
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 35
- Registration Number
- NCT00506545
Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)
Phase 2
Completed
- Conditions
- Cough
- Interventions
- Drug: Placebo Dose 1Drug: SCH 486757
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00506987
A Study of MK0657 in Parkinson's Disease Patients (0657-006)
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: MK0657
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00505843
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
Phase 2
Completed
- Conditions
- Paranoid Schizophrenia
- Interventions
- Drug: MK0249
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00506077
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)
Phase 1
Terminated
- Conditions
- Chronic Myelogenous LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
- Interventions
- Drug: MK0457Drug: dasatinib
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3
- Registration Number
- NCT00500006
Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)
Phase 3
Completed
- Conditions
- Varicella
- Interventions
- Biological: Varicella Virus Vaccine Live (Oka-Merck)
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00496327
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
Phase 3
Completed
- Conditions
- Papillomavirus Infections
- Interventions
- Biological: Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00496626
Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)
Phase 3
Completed
- Conditions
- GastroenteritisRotavirus
- Interventions
- Biological: Rotavirus Vaccine, Live, Oral, Pentavalent
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00496054
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
Phase 1
Completed
- Conditions
- Neoplasm
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 26
- Registration Number
- NCT00496353
Safety, Tolerability and Immunogenicity of Pneumovax 23 in Healthy Adults in India (V110-011)
Phase 3
Completed
- Conditions
- Pneumococcal Infection
- Interventions
- Biological: Pneumococcal Vaccine, Polyvalent (23-valent)
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 133
- Registration Number
- NCT00496093
© Copyright 2025. All Rights Reserved by MedPath